Eisai invests $15m in C₂N Diagnostics to advance Alzheimer’s disease diagnostics
In a significant move for the field of brain health diagnostics, C₂N Diagnostics, LLC, a pioneer in developing advanced diagnostic solutions for Alzheimer's disease, has ... Read More
Biogen strikes $600m deal with Pfizer for promising schizophrenia drug
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer's neurology drug candidate, PF-04958242, which is being developed to address cognitive ... Read More
University of Antwerp launches pioneering clinical trial to combat cognitive deficits in breast cancer patients
The University of Antwerp in Belgium has initiated an innovative clinical trial aimed at mitigating the cognitive deficits associated with breast cancer treatment, marking a ... Read More